Resultados: 23

Evaluation of the Whole-Blood Alere Q NAT Point-of-Care RNA Assay for HIV-1 Viral Load Monitoring in a Primary Health Care Setting in Mozambique

J. clin. microbiol; 54 (4), 2016
Viral load testing is the WHO-recommended monitoring assay for patients on HIV antiretroviral therapy (ART). Point-of-care (POC) assays may help improve access to viral load testing in resource-limited settings. We compared the performance of the Alere Q NAT POC viral load technology (Alere Technologies,...

Determinants of virological failure and antiretroviral drug resistance in Mozambique

J. antimicrob. chemother; 70 (9), 2015
Objectives: The objective of this study was to inform public health actions to limit first-line ART failure and HIV drug resistance in Mozambique. Methods: This was a cross-sectional study. HIV-1-infected adults on first-line ART for at least 1 year attending routine visits in the Manhiça District Hospi...

Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique

PLos ONE; 10 (7), 2015
Background: An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of HIV drug resistance (HIVDR) in antiretroviral (ART) naïve subjects initiating highly active antiretroviral treatment (HAART). Methodology/principal findings: To evaluate the pattern of drug res...

Incidence of HIV and the prevalence of HIV, hepatitis B and syphilis among youths in Maputo, Mozambique: a cohort study

PLos ONE; 10 (3), 2015
Background: Prevalence of HIV in Mozambique among individuals aged 15-49 years is 11.5%. The HIV prevalence is higher in women than in men across the country, peaking at ages 25-29 years and 35-39 years, respectively. In this study, we aimed at determining the prevalence and incidence of HIV, prevalence ...

Incidence of HIV and the prevalence of HIV, hepatitis B and syphilis among youths in Maputo, Mozambique: a cohort study

PLos ONE; 10 (3), 2015
Background: Prevalence of HIV in Mozambique among individuals aged 15-49 years is 11.5%. The HIV prevalence is higher in women than in men across the country, peaking at ages 25-29 years and 35-39 years, respectively. In this study, we aimed at determining the prevalence and incidence of HIV, prevalence ...

Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique

AIDS res. hum. retrovir; 30 (6), 2014
Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. It is the first approved antiviral agent to attack the HIV life cycle in its early stages. For HIV fusion to occur, the HR1 and HR2 domains in the gp...

Scaling up HIV viral load - lessons from the large-scale implementation of HIV early infant diagnosis and CD4 testing

J. int. aids soc; 20 (7), 2012
The scale-up of effective HIV viral load (VL) testing is an urgent public health priority. Implementation of testing is supported by the availability of accurate, nucleic acid based laboratory and point-of-care (POC) VL technologies and strong WHO guidance recommending routine testing to identify treatme...

HBV infection in untreated HIV-infected adults in Maputo, Mozambique

PLos ONE; 7 (9), 2012
Background HIV/ HBVcoinfected patients are at high risk of developing chronic HBV infection, liver cir rhosis and hepatocellular carcinoma. In Mozambique, where HIV prevalence is one of the highest in the world, HIV-infected patients are scarcely characterized in terms of HBV coin fection and 3TC-resista...

Evolution of primary HIV drug resistance in a subtype C dominated epidemic in Mozambique

PLos ONE; 7 (9), 2012
Objective: InMozambique, highly active antiretroviral treatment (HAART) was introduced in 2004 followed by decentralizationandexpansion, resulting inamorethan20-fold increase incoverageby2009. ImplementationofHIV drugresistancethresholdsurveys (HIVDR-TS) iscrucial inorder tomonitor theemergenceof transmi...

Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors

HIV proviral DNA integration into the host chromosome is carried out by integrase becoming an important target antiretroviral therapy. Raltegravir was the first integrase inhibitor approved for use in HIV therapy and elvitegravir is in the late phase of clinical development; both show good results in mon...